Public support for marijuana is at an all-time high. What does this mean for workers’ comp?

A novel bupivacaine formulation works as a 72-hour local anesthetic following shoulder surgery.

Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.

Orphengesic Forte has received a decision date of August 14, 2019.

Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.

Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.

More states allow for the legalization of recreational and medical marijuana, while others consider insurance reimbursement.

A study of 9,596 claimants who filled an opioid prescription found that 30% were still taking opioids 90 days later.

NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?

Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.